Anastrozole single-dose protocol in women with oligo- or anovulatory infertility

Results of a randomized phase II dose-response study

Donald Tredway, Joan C. Schertz, Daena Bock, George Hemsey, Michael Peter Diamond

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Objective: To compare the effects of anastrozole and clomiphene citrate (CC) on follicular development and ovulation in infertile women with ovulatory dysfunction. Design: Phase II, prospective, randomized, assessor-blind, multicenter, dose-finding, noninferiority study. Setting: Outpatient. Patient(s): Infertile women with ovulatory dysfunction, aged 18-35 years, and body mass index <35 kg/m2. Intervention(s): Single-dose anastrozole at 5 mg (n = 39), 10 mg (n = 39), 20 mg (n = 39), or 30 mg (n = 38) or a 5-day course of CC at 50 mg/d (n = 39) as starting doses. Main Outcome Measure(s): The primary endpoint was the ovulation rate in the first treatment cycle (cycle 1). Ovulation was defined as a midluteal phase serum P level ≥10 ng/mL or clinical pregnancy. Result(s): In cycle 1 the ovulation rates for a single dose of anastrozole at 5, 10, 20, and 30 mg were 46.2%, 41.0%, 23.1%, and 28.9%, respectively, whereas that for CC at 50 mg/d was 61.5%. Among women with fewer than six menses per year, the cumulative ovulation rates over three cycles were comparable in the anastrozole 5 mg (52.4%) and CC 50 mg/d (42.3%) groups. Conclusion(s): In terms of ovulation rates in cycle 1, single-dose anastrozole at 5, 10, 20, and 30 mg was not as effective as CC at 50 mg/d for 5 days (noninferiority was not shown).

Original languageEnglish (US)
JournalFertility and sterility
Volume95
Issue number5
DOIs
StatePublished - Jan 1 2011
Externally publishedYes

Fingerprint

Clomiphene
Ovulation
Infertility
Menstruation
anastrozole
Body Mass Index
Outpatients
Outcome Assessment (Health Care)
Pregnancy
Serum

Keywords

  • Anastrozole
  • aromatase inhibitor
  • clinical pregnancy
  • clomiphene citrate
  • ovulation
  • ovulatory dysfunction

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynecology

Cite this

Anastrozole single-dose protocol in women with oligo- or anovulatory infertility : Results of a randomized phase II dose-response study. / Tredway, Donald; Schertz, Joan C.; Bock, Daena; Hemsey, George; Diamond, Michael Peter.

In: Fertility and sterility, Vol. 95, No. 5, 01.01.2011.

Research output: Contribution to journalArticle

@article{1c1a362251ab4642b5915c2e2403f72e,
title = "Anastrozole single-dose protocol in women with oligo- or anovulatory infertility: Results of a randomized phase II dose-response study",
abstract = "Objective: To compare the effects of anastrozole and clomiphene citrate (CC) on follicular development and ovulation in infertile women with ovulatory dysfunction. Design: Phase II, prospective, randomized, assessor-blind, multicenter, dose-finding, noninferiority study. Setting: Outpatient. Patient(s): Infertile women with ovulatory dysfunction, aged 18-35 years, and body mass index <35 kg/m2. Intervention(s): Single-dose anastrozole at 5 mg (n = 39), 10 mg (n = 39), 20 mg (n = 39), or 30 mg (n = 38) or a 5-day course of CC at 50 mg/d (n = 39) as starting doses. Main Outcome Measure(s): The primary endpoint was the ovulation rate in the first treatment cycle (cycle 1). Ovulation was defined as a midluteal phase serum P level ≥10 ng/mL or clinical pregnancy. Result(s): In cycle 1 the ovulation rates for a single dose of anastrozole at 5, 10, 20, and 30 mg were 46.2{\%}, 41.0{\%}, 23.1{\%}, and 28.9{\%}, respectively, whereas that for CC at 50 mg/d was 61.5{\%}. Among women with fewer than six menses per year, the cumulative ovulation rates over three cycles were comparable in the anastrozole 5 mg (52.4{\%}) and CC 50 mg/d (42.3{\%}) groups. Conclusion(s): In terms of ovulation rates in cycle 1, single-dose anastrozole at 5, 10, 20, and 30 mg was not as effective as CC at 50 mg/d for 5 days (noninferiority was not shown).",
keywords = "Anastrozole, aromatase inhibitor, clinical pregnancy, clomiphene citrate, ovulation, ovulatory dysfunction",
author = "Donald Tredway and Schertz, {Joan C.} and Daena Bock and George Hemsey and Diamond, {Michael Peter}",
year = "2011",
month = "1",
day = "1",
doi = "10.1016/j.fertnstert.2010.11.068",
language = "English (US)",
volume = "95",
journal = "Fertility and Sterility",
issn = "0015-0282",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Anastrozole single-dose protocol in women with oligo- or anovulatory infertility

T2 - Results of a randomized phase II dose-response study

AU - Tredway, Donald

AU - Schertz, Joan C.

AU - Bock, Daena

AU - Hemsey, George

AU - Diamond, Michael Peter

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Objective: To compare the effects of anastrozole and clomiphene citrate (CC) on follicular development and ovulation in infertile women with ovulatory dysfunction. Design: Phase II, prospective, randomized, assessor-blind, multicenter, dose-finding, noninferiority study. Setting: Outpatient. Patient(s): Infertile women with ovulatory dysfunction, aged 18-35 years, and body mass index <35 kg/m2. Intervention(s): Single-dose anastrozole at 5 mg (n = 39), 10 mg (n = 39), 20 mg (n = 39), or 30 mg (n = 38) or a 5-day course of CC at 50 mg/d (n = 39) as starting doses. Main Outcome Measure(s): The primary endpoint was the ovulation rate in the first treatment cycle (cycle 1). Ovulation was defined as a midluteal phase serum P level ≥10 ng/mL or clinical pregnancy. Result(s): In cycle 1 the ovulation rates for a single dose of anastrozole at 5, 10, 20, and 30 mg were 46.2%, 41.0%, 23.1%, and 28.9%, respectively, whereas that for CC at 50 mg/d was 61.5%. Among women with fewer than six menses per year, the cumulative ovulation rates over three cycles were comparable in the anastrozole 5 mg (52.4%) and CC 50 mg/d (42.3%) groups. Conclusion(s): In terms of ovulation rates in cycle 1, single-dose anastrozole at 5, 10, 20, and 30 mg was not as effective as CC at 50 mg/d for 5 days (noninferiority was not shown).

AB - Objective: To compare the effects of anastrozole and clomiphene citrate (CC) on follicular development and ovulation in infertile women with ovulatory dysfunction. Design: Phase II, prospective, randomized, assessor-blind, multicenter, dose-finding, noninferiority study. Setting: Outpatient. Patient(s): Infertile women with ovulatory dysfunction, aged 18-35 years, and body mass index <35 kg/m2. Intervention(s): Single-dose anastrozole at 5 mg (n = 39), 10 mg (n = 39), 20 mg (n = 39), or 30 mg (n = 38) or a 5-day course of CC at 50 mg/d (n = 39) as starting doses. Main Outcome Measure(s): The primary endpoint was the ovulation rate in the first treatment cycle (cycle 1). Ovulation was defined as a midluteal phase serum P level ≥10 ng/mL or clinical pregnancy. Result(s): In cycle 1 the ovulation rates for a single dose of anastrozole at 5, 10, 20, and 30 mg were 46.2%, 41.0%, 23.1%, and 28.9%, respectively, whereas that for CC at 50 mg/d was 61.5%. Among women with fewer than six menses per year, the cumulative ovulation rates over three cycles were comparable in the anastrozole 5 mg (52.4%) and CC 50 mg/d (42.3%) groups. Conclusion(s): In terms of ovulation rates in cycle 1, single-dose anastrozole at 5, 10, 20, and 30 mg was not as effective as CC at 50 mg/d for 5 days (noninferiority was not shown).

KW - Anastrozole

KW - aromatase inhibitor

KW - clinical pregnancy

KW - clomiphene citrate

KW - ovulation

KW - ovulatory dysfunction

UR - http://www.scopus.com/inward/record.url?scp=79952990301&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952990301&partnerID=8YFLogxK

U2 - 10.1016/j.fertnstert.2010.11.068

DO - 10.1016/j.fertnstert.2010.11.068

M3 - Article

VL - 95

JO - Fertility and Sterility

JF - Fertility and Sterility

SN - 0015-0282

IS - 5

ER -